Cargando…

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer

PURPOSE: Metastatic breast cancer (MBC) has a heterogeneous clinical course. We sought to develop a prognostic model for overall survival (OS) that incorporated contemporary tumor and clinical factors for estimating individual prognosis. METHODS: We identified patients with MBC from our institution...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barcenas, Carlos H., Song, Juhee, Murthy, Rashmi K., Raghavendra, Akshara S., Li, Yisheng, Hsu, Limin, Carlson, Robert W., Tripathy, Debu, Hortobagyi, Gabriel N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807018/ https://www.ncbi.nlm.nih.gov/pubmed/34351787 http://dx.doi.org/10.1200/CCI.21.00020

Ejemplares similares

Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice
por: Murthy, Rashmi K., et al.
Publicado: (2020)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
por: Mouabbi, Jason A., et al.
Publicado: (2022)

The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2022)

Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2021)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer
por: Garber, Haven R., et al.
Publicado: (2022)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy
por: Chien, Christine, et al.
Publicado: (2022)

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
por: Mouabbi, Jason A., et al.
Publicado: (2023)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer
por: Villodre, Emilly S., et al.
Publicado: (2020)

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
por: Lobbezoo, D J A, et al.
Publicado: (2015)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity
por: Reddy, S M, et al.
Publicado: (2018)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors
por: Sinha, Arup K., et al.
Publicado: (2017)

Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer
por: Kida, Kumiko, et al.
Publicado: (2020)

Prognostic molecular markers in early breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2004)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care
por: Tripathy, Debu
Publicado: (2015)

Androgen receptor expression on circulating tumor cells in metastatic breast cancer
por: Fujii, Takeo, et al.
Publicado: (2017)

Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process
por: Khodadadi-Jamayran, Alireza, et al.
Publicado: (2018)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2019)

The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
por: Sun, Shujuan, et al.
Publicado: (2023)

Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
por: Malmgren, Judith A., et al.
Publicado: (2017)

Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients
por: McKenzie, Hayley S., et al.
Publicado: (2020)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer
por: Zhang, Jun-Yu, et al.
Publicado: (2021)

Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2022)

Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
por: Pal, Sumanta K, et al.
Publicado: (2012)

De novo and recurrent metastatic breast cancer – A systematic review of population-level changes in survival since 1995
por: Lord, SJ, et al.
Publicado: (2022)

Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2022)

Prognostic Score for De Novo Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit
por: Ji, Lei, et al.
Publicado: (2021)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer
por: Nanou, Afroditi, et al.
Publicado: (2023)

Locoregional therapy in de novo metastatic breast cancer. The unanswered question
por: Cardoso, Maria-Joao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g888q1c1151k7d238ugeqomheo